Last reviewed · How we verify

AZT+3TC+ABV (Trizivir)

Fundacion SEIMC-GESIDA · FDA-approved active Small molecule

Trizivir is a fixed-dose combination of three nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase to prevent viral replication.

Trizivir is a fixed-dose combination of three nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase to prevent viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.

At a glance

Generic nameAZT+3TC+ABV (Trizivir)
Also known asLPV/r (Kaletra)
SponsorFundacion SEIMC-GESIDA
Drug classNucleoside reverse transcriptase inhibitor (NRTI) combination
TargetHIV reverse transcriptase
ModalitySmall molecule
Therapeutic areaInfectious Disease / Virology
PhaseFDA-approved

Mechanism of action

AZT (zidovudine), 3TC (lamivudine), and ABV (abacavir) are all NRTIs that inhibit HIV reverse transcriptase by competing with natural nucleotides and causing chain termination during viral DNA synthesis. This combination provides synergistic antiretroviral activity against HIV-1 by targeting the same enzyme through multiple mechanisms, reducing the likelihood of resistance development compared to monotherapy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: